Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced expanding its collaboration with Valo Health, Inc. (Valo) in a deal worth up to...
Novo Nordisk’s $4.6 Billion Collaboration with Valo Health
Apollo Therapeutics’ Exclusive License Agreement with Sunshine Lake Pharma
Ropes & Gray represented Apollo Therapeutics in the transaction. Apollo Therapeutics Group Limited (“Apollo”) and Sunshine Lake Pharma Co., Ltd. have entered into an exclusive license...
AvenCell Therapeutics’ $112 Million Series B Funding Round
Ropes & Gray represented AvenCell Therapeutics in the transaction, and Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction. AvenCell Therapeutics...
Serán Bioscience’s $200 Million Growth Transaction
Ropes & Gray represented Bain Capital Life Sciences in the transaction. Serán Bioscience (“Serán”), a leading contract development and manufacturing organization (CDMO), announced a strategic growth...
Vapotherm’s Merger and Take-Private
Ropes & Gray acted as legal counsel to Vapotherm, Inc. in the transaction. Cooley acted as legal counsel to Perceptive and Latham & Watkins acted as...
Takeda Pharmaceuticals’ $1.2 Billion License Agreement with Degron Therapeutics
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
Erasca’s In-Licensing of RAS-Targeting Franchise
Ropes & Gray advised Erasca, Inc. on the deal. Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, announced it has entered into an exclusive license agreement...
Pfizer’s Strategic Collaboration with Flagship Pioneering
Ropes & Gray advised Pfizer on the deal. Pfizer announced a strategic collaboration with Flagship Pioneering to create a new pipeline of innovative medicines. The collaboration...
Pfizer’s $25 Million Strategic Investment in CellCentric
Ropes & Gray advised Pfizer on the deal. Pfizer announced its strategic investment in and collaboration with CellCentric, which includes $25 million to help finance further development...
Ovid Therapeutics’ Collaboration with Graviton Bioscience
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a collaboration with Graviton Bioscience Corporation under which Ovid obtained exclusive rights to develop...
National Resilience’s $110 Million Alliance with Bluebird Bio to Develop Cell Therapies
Ropes & Gray advised National Resilience on the deal. National Resilience, Inc., a biopharmaceutical manufacturing specialist, closed a strategic alliance with bluebird bio, Inc., to accelerate...
SmartLabs’ $250 Million Series B Financing
Ropes & Gray represented SmartLabs in the transaction. SmartLabs, a Boston-based Laboratory-as-a-Service leader, raised $250 million in a Series B financing that will be used to help...